Innate Pharma SA (IPHA) — 6-K Filings

All 6-K filings from Innate Pharma SA. Browse 8 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (8)

Innate Pharma Files 6-K Report — Apr 23, 2026 Risk: low
Innate Pharma SA filed a 6-K report on April 23, 2026. The filing includes a document titled 'EX-99.1' and a complete submission text file. The company's mailin
6-K Filing — Apr 17, 2026
Innate Pharma Files 6-K Report — Apr 13, 2026 Risk: low
Innate Pharma SA filed a 6-K report on April 13, 2026. The filing includes a document labeled EX-99.1, which is an exhibit to the report. The company is based i
Innate Pharma Files 6-K Report — Apr 13, 2026 Risk: low
Innate Pharma SA filed a 6-K report on April 13, 2026. The filing includes a 6-K document and an exhibit (EX-99.1). The company's mailing and business address i
Innate Pharma Files 6-K Report — Apr 8, 2026 Risk: low
Innate Pharma SA filed a Form 6-K on April 8, 2026. This report is for a foreign issuer and includes documents such as the 6-K itself and Exhibit 99.1. The fili
6-K Filing — Apr 3, 2026
Innate Pharma Files 6-K Report — Apr 2, 2026 Risk: low
Innate Pharma SA filed a 6-K report on April 2, 2026. The filing includes exhibit EX-99.1 and a complete submission text file. The company's mailing and busines
Innate Pharma Files Routine 6-K Report on March 26, 2026 — Mar 26, 2026
Innate Pharma SA filed a 6-K report on March 26, 2026, indicating a routine foreign issuer report. This filing, with accession number 0001628280-26-021168, incl

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX